These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17153267)

  • 1. [Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
    Calvo-Villas JM; Tapia Torres M; Govantes Rodríguez J; Carreter de Granda E; Sicilia Guillén F
    Med Clin (Barc); 2006 Oct; 127(15):576-9. PubMed ID: 17153267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
    Dimopoulos MA; Kastritis E; Bamia C; Melakopoulos I; Gika D; Roussou M; Migkou M; Eleftherakis-Papaiakovou E; Christoulas D; Terpos E; Bamias A
    Ann Oncol; 2009 Jan; 20(1):117-20. PubMed ID: 18689864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
    Grbic JT; Black DM; Lyles KW; Reid DM; Orwoll E; McClung M; Bucci-Rechtweg C; Su G
    J Am Dent Assoc; 2010 Nov; 141(11):1365-70. PubMed ID: 21037195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
    Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
    Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
    J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
    J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.
    Van Poznak CH; Unger JM; Darke AK; Moinpour C; Bagramian RA; Schubert MM; Hansen LK; Floyd JD; Dakhil SR; Lew DL; Wade JL; Fisch MJ; Henry NL; Hershman DL; Gralow J
    JAMA Oncol; 2021 Feb; 7(2):246-254. PubMed ID: 33331905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
    Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
    J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
    La Verde N; Bareggi C; Garassino M; Borgonovo K; Sburlati P; Pedretti D; Bianchi C; Perrone S; Mihali D; Cobelli S; Mantica C; Rizzo A; Farina G
    Support Care Cancer; 2008 Nov; 16(11):1311-5. PubMed ID: 18663482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
    Rathbone EJ; Brown JE; Marshall HC; Collinson M; Liversedge V; Murden GA; Cameron D; Bell R; Spensley S; Agrawal R; Jyothirmayi R; Chakraborti P; Yuille F; Coleman RE
    J Clin Oncol; 2013 Jul; 31(21):2685-91. PubMed ID: 23796998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
    Tosi P; Zamagni E; Cangini D; Tacchetti P; Di Raimondo F; Catalano L; D'Arco A; Ronconi S; Cellini C; Offidani M; Perrone G; Ceccolini M; Brioli A; Tura S; Baccarani M; Cavo M
    Blood; 2006 Dec; 108(12):3951-2. PubMed ID: 17114572
    [No Abstract]   [Full Text] [Related]  

  • 13. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
    Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
    Van Poznak C; Estilo C
    Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Avascular osteonecrosis of the jaws induced by diphosphonates].
    Lannoy D; Decaudin B; Barrier F; Bemba M; Wierre L; Pignon JM; Horrent S; Résibois JP; Wetterwald M; Odou P
    Therapie; 2006; 61(4):363-5. PubMed ID: 17124954
    [No Abstract]   [Full Text] [Related]  

  • 17. [Osteonecrosis associated with the use of biphosphonates: Case report].
    Anguita C T; Agurto P J; Roa E I; Laissle C G
    Rev Med Chil; 2006 Sep; 134(9):1161-5. PubMed ID: 17171218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.
    Aguiar Bujanda D; Bohn Sarmiento U; Cabrera Suárez MA; Aguiar Morales J
    Ann Oncol; 2007 Mar; 18(3):556-60. PubMed ID: 17082512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM; Arora S; Farag AF; Guber HA
    Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.